June 5, 2023

Volume XIII, Number 156


June 04, 2023

Subscribe to Latest Legal News and Analysis

June 03, 2023

Subscribe to Latest Legal News and Analysis

June 02, 2023

Subscribe to Latest Legal News and Analysis

U.S. Supreme Court To Determine Authority, Review Standard For Government Dismissals Of False Claims Act Qui Tam Actions


U.S. Supreme Court set to decide the standard dictating the government’s ability to dismiss qui tam actions it previously declined to pursue

Decision contemplates a four-way Circuit split articulating varying standards for government dismissal 

The outcome of the Polansky case will undoubtedly affect government interventions and government-initiated motions to dismiss moving forward

Last week, the U.S. Supreme Court granted a whistleblower’s (otherwise known as a relator) request for review in U.S. ex rel. Polansky v. Executive Health Resources, Inc. – asking the Court to weigh in on an ongoing Circuit split regarding the government’s authority to dismiss False Claims Act litigation after initially declining to intervene.  

The petition in Polansky presents two questions for review: Preliminarily, does the government retain the authority to dismiss a previously declined False Claims Act suit? Second, if the Court determines the government retains such authority, what standard dictates when the government may dismiss a non-intervened lawsuit?

Importantly, the first question is not the issue presented by the current Circuit split. Instead, the current split concerns the second question relating to what standard applies when the government seeks to dismiss a qui tam suit. At this time, there are four approaches to this standard:

  1. The Ninth and Tenth Circuits apply a two-step burden-shifting analysis, also referred to as the “rational relation” approach. Under this standard, the government must first identify “a valid government purpose” and establish a “rational relation between dismissal and accomplishment of that purpose.” If the government can do so, the court then requires the relator “to demonstrate that dismissal is fraudulent, arbitrary, and capricious, or illegal.” The Tenth Circuit has also adopted this “rational relation” approach.

  2. The District of Columbia Circuit applies a rule endorsing an “unfettered right” for the government to dismiss qui tam suits, even at late stages. The D.C. Circuit has held that the purpose of the hearing required by U.S. Code Section 3730(c)(2)(A) is “simply to give the relator a formal opportunity to convince the government not to end the case.”

  3. The Third Circuit (in the case underlying this petition) and the Seventh Circuit have held that in order to dismiss a qui tam action, the government must successfully intervene in the action under Section 3720(c), which requires the government to demonstrate that there is “good cause” for a late intervention. However, once the government has intervened, these Circuits apply Rule 41 of the Federal Rules of Civil Procedure (the standard for voluntary dismissals in civil cases) in conjunction with the False Claims Act’s hearing requirement to determine whether to grant the government’s motion to dismiss. The U.S. Court of Appeals for the Eleventh Circuit also applies Rule 41 to evaluate the government’s motion to dismiss but does not require the government to formally intervene before submitting the motion.

  4. The First Circuit adopted a fourth standard in January 2022. Specifically, it held the government is not required to justify its motion to dismiss. Instead, the government must provide its rationale for seeking dismissal so that the relator, at the required hearing, has the opportunity to convince the government to withdraw its motion. Unless the relator demonstrates the government is transgressing constitutional limitations or perpetrating a fraud on the court, the court is required to dismiss the case under this standard.

Notably, the Supreme Court accepted the relator’s petition in Polansky over the government’s opposition, which argued the Circuit courts have unanimously accepted the government’s dismissal authority and any “modest differences among the standards” set forth “should very rarely if ever be outcome determinative.” 

The Supreme Court’s opinion in this matter, and ultimate resolution of the current Circuit split, may pose significant implications for both relators and defendants in False Claims Act litigation – particularly those in the healthcare industry. In February 2022, the U.S. Department of Justice (DOJ) reported that of the more than $5.6 billion in settlements and judgments it collected in 2021, more than $5 billion “related to matters involving the healthcare industry, including drug and medical device manufacturers, managed care providers, hospitals, pharmacies, hospice organizations, laboratories, and physicians.” In addition, out of the 598 qui tam actions initiated in 2021, 398 were healthcare-related.

Should the Court determine here that the government lacks authority to dismiss a qui tam action where it initially declines to intervene, the government may seek to extend the seal periods for these cases beyond typical limits. Such a bright-line rule could also result in an increased number of government interventions and government-initiated motions to dismiss at the outset of False Claims Act litigation – at least with respect to the types of cases that are the subject of the 2018 Granston Memo and articulated in Section 4-4.111 of the DOJ’s Justice Manual (e.g., truly meritless or parasitic cases, cases that interfere with agency policies or programs or touch on classified information or national security interests, or those cases that present egregious procedural errors or encourage waste of government resources). In 2021, approximately $452 million, or 30 percent of all healthcare-related False Claims Act qui tam recoveries, resulted from declined actions. That number could change if the government determines it now wants to intervene in those matters. 

The more likely outcome in Polansky is that the Supreme Court will affirm the government’s authority to dismiss qui tam actions following a declination to intervene and instead focus on resolving the applicable standard for government dismissals generally. If the Court adopts the D.C. Circuit’s “unfettered right” standard, defendants may have an easier time convincing the government to pursue previously declined dismissals where it becomes clear the relator’s claims are baseless. If the Court adopts another, more demanding standard such as those followed by the Ninth and Tenth Circuits, the government may hesitate to pursue these dismissals in the future. Regardless, until the Supreme Court decides this issue, it is likely the government will demonstrate reluctance to dismiss qui tam actions in which it initially declines to intervene. 

© 2023 BARNES & THORNBURG LLPNational Law Review, Volume XII, Number 179

About this Author

John E. Kelly D.C. Healthcare Attorney Barnes & Thornburg

Chair of Barnes & Thornburg’s Healthcare Department and Industry Practice, John advises and defends companies and individuals in criminal prosecutions and civil litigation involving health care fraud and abuse issues, including the False Claims Act, Anti-Kickback Statute and Stark Law, the Food, Drug and Cosmetic Act (FDCA), the Controlled Substances Act (CSA), the Foreign Corrupt Practices Act (FCPA), and other regulatory and compliance issues. He is well versed in the needs of providers, hospitals, health systems, clinical labs, pharmacies, pharmacy benefit...

Jacquelyn Papish Federal Regulations and Criminal Justice Litigation Attorney Barnes & Thornburg Law Firm

Jackie regularly represents clients in False Claims Act (FCA) litigation and related civil and criminal investigations by the U.S. Department of Justice (DOJ), Department of Health and Human Services Office of Inspector General (HHS-OIG), Food and Drug Administration (FDA), Drug Enforcement Administration (DEA), and other federal and state regulators.  Her work is concentrated on the healthcare and life sciences industries but has spanned a number of others, including technology and financial services.

Jackie’s strength is in helping her clients feel at ease in the face of high-...


A.J. Bolan is a straight-shooter and passionate litigator who is adamant about ensuring that clients’ positions are heard and needs are met. A.J. advises and represents clients in response to government actions, investigations and claims brought under various federal and state regulations, and assists corporations and individuals in internal investigations.

In addition, A.J. regularly counsels healthcare companies – ranging from individual physician-owned entities to large nonprofit healthcare systems – on healthcare fraud and abuse matters...